The Rate of Breast Fibroglandular Enhancement During Dynamic Contrast-enhanced MRI Reflects Response to Neoadjuvant Therapy

Overview

Journal Eur J Radiol

Specialty Radiology

Date 2021 Jan 17

PMID 33454460

Citations 2

Authors

John Virostko

Garrett Kuketz

Erin Higgins

Chengyue Wu

Anna G Sorace

Julie C DiCarlo

Sarah Avery

Debra Patt

Boone Goodgame

Thomas E Yankeelov

Affiliations

Soon will be listed here.

Abstract

Purpose: This study assesses the rate of enhancement of breast fibroglandular tissue after administration of a magnetic resonance imaging (MRI) gadolinium-based contrast agent and determines its relationship with response to neoadjuvant therapy (NAT) in women with breast cancer.

Method: Women with locally advanced breast cancer (N = 19) were imaged four times over the course of NAT. Dynamic contrast-enhanced (DCE) MRI was acquired after administration of a gadolinium-based contrast agent with a temporal resolution of 7.27 s. The tumor, fibroglandular tissue, and adipose tissue were semi-automatically segmented using a manually drawn region of interest encompassing the tumor followed by fuzzy c-means clustering. The rate and relative intensity of signal enhancement were calculated for each voxel within the tumor and fibroglandular tissue.

Results: The rate of fibroglandular tissue enhancement after contrast agent injection declined by an average of 29 % over the course of NAT. This decline was present in 16 of the 19 patients in the study. The rate of enhancement is significantly higher in women who achieve pathological complete response (pCR) after both 1 cycle (68 % higher, p < 0.05) and after 3-5 cycles of NAT (58 % higher; p < 0.05). The relative intensity of fibroglandular enhancement correlates with the rate of enhancement (R = 0.64, p < 0.001) and is higher in women who achieve pCR after both 1 cycle and after 3-5 cycles of NAT (p < 0.05, both timepoints).

Conclusion: The rate of fibroglandular tissue enhancement declines over the course of therapy, provides novel information not reflected by tumoral measures, and may predict pathological response early in the course of therapy, with smaller declines in enhancement in women who achieve favorable response.

Citing Articles

Development and Internal Validation of a Preoperative Prediction Model for Sentinel Lymph Node Status in Breast Cancer: Combining Radiomics Signature and Clinical Factors.

Wang C, Chen X, Luo H, Liu Y, Meng R, Wang M Front Oncol. 2021; 11:754843.

PMID: 34820327 PMC: 8606782. DOI: 10.3389/fonc.2021.754843.

Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting.

Jarrett A, Kazerouni A, Wu C, Virostko J, Sorace A, DiCarlo J Nat Protoc. 2021; 16(11):5309-5338.

PMID: 34552262 PMC: 9753909. DOI: 10.1038/s41596-021-00617-y.

References

Hilal T, Covington M, Kosiorek H, Zwart C, Ocal I, Pockaj B . Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy. Breast J. 2018; 24(6):1010-1014. DOI: 10.1111/tbj.13101. View

Braman N, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P . Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 2017; 19(1):57. PMC: 5437672. DOI: 10.1186/s13058-017-0846-1. View

Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen Y, Hsu H . Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011; 3(4):490-6. PMC: 3698966. DOI: 10.1039/c0ib00089b. View

Virostko J, Hainline A, Kang H, Arlinghaus L, Abramson R, Barnes S . Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. J Med Imaging (Bellingham). 2017; 5(1):011011. PMC: 5701084. DOI: 10.1117/1.JMI.5.1.011011. View

Esserman L, Berry D, DeMichele A, Carey L, Davis S, Buxton M . Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012; 30(26):3242-9. PMC: 3434983. DOI: 10.1200/JCO.2011.39.2779. View

Olshen A, Wolf D, Jones E, Newitt D, J van t Veer L, Yau C . Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018; 5(1):011014. PMC: 5741993. DOI: 10.1117/1.JMI.5.1.011014. View

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

Orel S, SCHNALL M . MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology. 2001; 220(1):13-30. DOI: 10.1148/radiology.220.1.r01jl3113. View

Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J . Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol. 2008; 190(6):1630-6. DOI: 10.2214/AJR.07.2533. View

10.

Hylton N, Blume J, Bernreuter W, Pisano E, Rosen M, Morris E . Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012; 263(3):663-72. PMC: 3359517. DOI: 10.1148/radiol.12110748. View

11.

Liao G, Bancroft L, Strigel R, Chitalia R, Kontos D, Moy L . Background parenchymal enhancement on breast MRI: A comprehensive review. J Magn Reson Imaging. 2019; 51(1):43-61. PMC: 7207072. DOI: 10.1002/jmri.26762. View

12.

Jung Y, Jeong S, Kang D, Moon Y, Kim T . Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis. Eur J Radiol. 2018; 103:84-89. DOI: 10.1016/j.ejrad.2018.04.009. View

13.

Tudorica A, Oh K, Chui S, Roy N, Troxell M, Naik A . Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI. Transl Oncol. 2016; 9(1):8-17. PMC: 4800060. DOI: 10.1016/j.tranon.2015.11.016. View

14.

You C, Gu Y, Peng W, Li J, Shen X, Liu G . Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer. Acta Radiol. 2017; 59(7):806-812. DOI: 10.1177/0284185117738560. View

15.

Shin H, Park J, Shin K, Kim H, Cha J, Chae E . Characterization of tumor and adjacent peritumoral stroma in patients with breast cancer using high-resolution diffusion-weighted imaging: Correlation with pathologic biomarkers. Eur J Radiol. 2016; 85(5):1004-11. DOI: 10.1016/j.ejrad.2016.02.017. View

16.

Yankeelov T, Lepage M, Chakravarthy A, Broome E, Niermann K, Kelley M . Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007; 25(1):1-13. PMC: 2634832. DOI: 10.1016/j.mri.2006.09.006. View

17.

Kuhl C, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J . Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999; 211(1):101-10. DOI: 10.1148/radiology.211.1.r99ap38101. View

18.

Preibsch H, Wanner L, Bahrs S, Wietek B, Siegmann-Luz K, Oberlecher E . Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol. 2015; 26(6):1590-6. DOI: 10.1007/s00330-015-4011-x. View

19.

King V, Kaplan J, Pike M, Liberman L, Dershaw D, Lee C . Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J. 2012; 18(6):527-34. DOI: 10.1111/tbj.12002. View

20.

H M van der Velden B, Dmitriev I, Loo C, Pijnappel R, Gilhuijs K . Association between Parenchymal Enhancement of the Contralateral Breast in Dynamic Contrast-enhanced MR Imaging and Outcome of Patients with Unilateral Invasive Breast Cancer. Radiology. 2015; 276(3):675-85. DOI: 10.1148/radiol.15142192. View